Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

GLOBAL MARKETS-Biden transition and vaccine hopes drive up stocks, oil and bitcoin

Tue, 24th Nov 2020 10:52

* Risk currencies gain as uncertainty retreats

* Vaccine could be released by mid-December

* Trump, government officials nod to formal Biden transition

* Bitcoin hits 19,000

* For a Reuters live blog on U.S., UK and European stock
markets,
click LIVE/ or type LIVE/ in a news window.

By Lawrence White and Julie Zhu

LONDON/HONG KONG, Nov 24 (Reuters) - Stocks, oil and risk
currencies including bitcoin gained on Tuesday as the formal
go-ahead for U.S. President-elect Joe Biden to begin his
transition burnished a November already boosted by COVID-19
vaccines.

European markets tracked gains in Asian and U.S. equities,
with the broad-based STOXX 600 index climbing 0.6%
and Brent crude climbing to its highest level
since March at $46.52 a barrel. Safe haven assets such as
gold fell.

After weeks of legal challenges to the election results,
U.S. General Services Administration chief Emily Murphy wrote to
Biden on Monday informing him the formal handover process could
begin.

President Donald Trump tweeted that he had told his team "do
what needs to be done with regard to initial protocols", an
indication he was moving towards a transition.

"Markets have been constrained by very high levels of
uncertainty on the U.S. political front and around vaccines for
weeks, so with those two going away investors are considering
the prospect of a return to normality in 2021," said Emmanuel
Cau, head of European equity strategy at Barclays.

Reports that Biden plans to nominate former Federal Reserve
Chair Janet Yellen to become the next Treasury Secretary further
boosted U.S. stocks on expectations she would pursue more
conventional policies than the outgoing Steven Mnuchin.

Futures for the S&P 500 rose 0.7% in early European
trading hours, putting the 49-country MSCI world stocks index on
course to set a new record high later.

Japan's Nikkei jumped 2.5% to its highest level
since May 1991 overnight, with energy, real estate and financial
shares leading the advance.

Asia-Pacific shares outside Japan had ticked
up 0.4%. Australia's S&P/ASX 200 was 1.26% stronger,
touching its highest level in almost nine months, with energy
stocks leading the pack there.

Seoul's Kospi was 0.6% higher as was Hong Kong's
Hang Seng which rose 0.4%. China blue-chips
were an outlier however, edging down 0.6%, as
investors booked profits following recent strong gains.

Some analysts say a Biden presidency, which could mean more
negotiation room for Washington and Beijing, would not make a
big difference for China's equities market, as they expected
little change in broad U.S. policy towards China.

The progress made on COVID-19 vaccines, which had
underpinned Wall Street overnight, helped keep risk appetite
elevated as it boosted optimism about a quicker revival for the
global economy.

AstraZeneca and Oxford University said on Monday
that their COVID-19 vaccine, which is cheaper to make, easier to
distribute and faster to scale-up than its rivals, could be as
much as 90% effective.

RISK ON

The New Zealand dollar was among the currency
gainers, rising as much as 0.9% to a two-year high of $0.6986 as
its central bank said house prices, which have been storming
higher this year, could be included in its inflation basket.

The euro was gaining towards $1.19 again and the
dollar index, which tracks the greenback against a basket
of six major rivals, nudged down to 92.242.

Bitcoin hit $19,000 for the first time in nearly
three years, homing in on its all-time high of just under
$20,000 as demand for assets perceived as resistant to inflation
grows.

Also spurred on by the vaccine hopes, oil reached levels not
seen since before the coronavirus began to spread rapidly in
March and decimated demand.

Brent crude futures rose 45 cents, or 1%, to $46.51
a barrel to add to a more than 20% surge this month, while U.S.
West Texas Intermediate crude added 46 cents, or 1.1%, to
$43.52.

"Progress on developing and distributing a vaccine de-risks
the path back to normal for oil markets," said Stephen Innes,
chief global markets strategist at financial services firm Axi.

Adding to the positive near-term tone in markets was better
than expected economic news from Germany, where gross domestic
product grew by a record 8.5% in the third quarter as household
spending recovered. The reading marked an upward revision to an
earlier flash estimate of 8.2% growth.

The Ifo institute's survey of business morale pointed to
fears of a recession to come, however, as the business climate
index fell to 90.7 from a downwardly revised 92.5 in October.

In the bond markets, the yield on the U.S. benchmark 10-year
notes rose slightly to 0.87% as did those on most
European government bonds. Germany's 10-year yield was up 1
basis point to -0.57% in early trade.

Gold continued to lose its shine too, falling 1% to
$1,817 an ounce having dropped 10% this month.

(Reporting by Lawrence White, Julie Zhu and Katanga Johnson;
editing by Shri Navaratnam, Philippa Fletcher and Nick Macfie
For Reuters Live Markets blog on European and UK stock markets,
please click on:)

Related Shares

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...

2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.